The Uro-GHD features a 1280x720 pixel sensor, a first in portable, single-use endoscopy. LOS ALTOS, CA / ACCESSWIRE / April 7, 2023 / UroViu Corp (www.uroviu.com) has launched the new Uro-GHD, a ...

Adding Bladder EpiCheck to cystoscopy for non-muscle invasive bladder cancer (NMIBC) surveillance and, if positive, performing biopsy under photodynamic diagnosis (PDD), significantly improved ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...

UroViu Corporation, a company develops a suite of diagnostic and therapeutic endoscopic products, has announced that its Uro-V single-use diagnostic cystoscopic system has received 510(k) clearance ...

A cystoscopy is a procedure that involves inserting a tool into the urethra and up into the bladder to examine these organs. The tool is a cystoscope — a thin, flexible instrument with a light and a ...

Bladder biopsy of normal-looking mucosa, as determined by cystoscopy, might not add clinical value in patients with positive voided-urine cytology after treatment of non-muscle-invasive bladder cancer ...

ORANGEBURG, N.Y., May 13, 2011 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI) announced today the introduction by Stryker Corporation ("Stryker") of the new line of EndoSheath Cystoscopy ...

SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of ...

A single-dose of URO-902 may prove to be an effective treatment strategy for women with overactive bladder and urge urinary incontinence, according to findings from the final analysis of a phase IIa ...